The healthcare and biotech sector saw fundraising activity dominate proceedings, with two AIM-listed companies tapping shareholders for fresh capital while a third secured a significant intellectual property win. Futura Medical (AIM:FUM)'s dual announcement of a discounted placing and a formal sale process under the Takeover Code marked the day's most consequential development, sending its shares down sharply even as the company argued its true value lies elsewhere.
Futura Medical opens door to sale after cash raise
Futura Medical (AIM:FUM) has conditionally raised approximately £1.6 million through a placing and subscription while simultaneously launching a formal sale process under the Takeover Code, a move that opens the door to a sale of the company or its underlying assets. The developer of erectile dysfunction treatment Eroxon and the female sexual health platform WSD4000 saw its shares fall 15.152% to 0.28p as the market digested a deeply discounted raise alongside the strategic review. The new shares were issued at 0.2p, a discount of approximately 37.6% to the previous closing price of 0.32p, and will represent roughly 60.1% of the enlarged share capital once the deal completes.
A further retail offer via the BookBuild platform aims to raise up to £150,000 on top of the institutional placing and subscription. The board argued that Futura's current market valuation fails to capture the strategic worth of its pipeline, pointing to WSD4000's estimated peak annual consumer sales potential of over $400 million, against a combined figure of more than $250 million for Eroxon and Eroxon Intense. Proceeds are earmarked to extend the company's cash runway into February 2027, fund the sale process itself, and support continued commercial development across all three lead products. Shareholders will vote on the fundraising resolutions at a general meeting on 23 September, with the new shares expected to begin trading roughly 25 September.
"This allowance strengthens the proprietary position around SVN-114 in a large PTSD market attracting significant pharmaceutical investment," said Anthony Tennyson, Chief Executive.
Specialist adviser Present Value has been appointed alongside Nominated Adviser Panmure Liberum to run a process that could result in asset sales, licensing arrangements, or an outright sale of the whole company. The dilution embedded in the raise and the steep discount to the prior closing price signal a board under real pressure to shore up its balance sheet even as it markets the company's pipeline assets to potential acquirers, a combination that leaves existing shareholders exposed to further dilution risk should a transaction fail to materialise before the extended runway expires.
Futura Medical opens £150,000 window for retail holders
Futura Medical (AIM:FUM) has launched a retail offer to existing shareholders through the BookBuild platform, seeking up to £150,000 via the issue of up to 75 million new shares priced at 0.2p each. The offer runs alongside the company's separately announced £1.6 million conditional fundraising, which comprises a firm placing, a conditional placing and a conditional subscription, and shares the same issue price, a discount of approximately 37.63% to the 0.32p closing middle market price recorded on 2 September.
Futura said it valued the loyalty of its retail shareholder base, which has supported the company alongside institutional investors since its AIM admission in 2003. Turner Pope Investments is coordinating the retail offer, with a minimum subscription of £100 per investor and no maximum cap set. The window opened at 7:05am on 3 September and was due to close at 4:30pm the following day.
Extending participation to retail holders on identical terms to the institutional raise gives smaller shareholders a chance to avoid dilution from the wider fundraising, though the tight 33-hour window and modest £150,000 target underline that the retail tranche is a gesture toward loyalty rather than a material contributor to the company's overall cash position ahead of its sale process.
Renalytix opens retail window on £10.1 million placing
Renalytix (LSE:RENX), the kidney disease diagnostics company, is offering up to 16.67 million new shares to retail investors through the Winterflood Retail Access Platform, seeking to raise up to £1 million at 6p per share. The offer runs alongside a larger £10.1 million placing and subscription announced on 1 September, priced at the same 6p level, of which £0.9 million remains conditional on shareholder approval at a forthcoming general meeting. That 6p price represents a premium of approximately 44.6% to Renalytix's mid-market closing price of 4.15p on 28 August, and a 139% premium to its 90-day average closing price.
Proceeds from the retail offer will be applied to the same purposes as the institutional placing, though the two instruments are structured separately. Completion of the retail offer depends on the placing completing, but the placing itself does not depend on retail take-up. Eligible UK investors, whether new or existing shareholders, can apply through participating brokers or wealth managers, subject to a £100 minimum subscription.
The premium pricing on both tranches marks a notable contrast with Futura's heavily discounted raise, suggesting Renalytix retains stronger negotiating leverage with new and existing backers even as it seeks fresh capital, though the £900,000 slice still hinges on a shareholder vote yet to come.
Solvonis secures composition patent for PTSD drug candidate
Solvonis Therapeutics (LSE:SVNS), a late clinical-stage biopharmaceutical company developing small-molecule treatments for central nervous system disorders, said the European Patent Office has issued a Notice of Allowance for a composition-of-matter patent covering its post-traumatic stress disorder programme. The patent relates to SVN-114, the company's lead PTSD candidate, and represents the strongest form of pharmaceutical intellectual property protection available, covering the underlying chemical compounds themselves rather than merely their formulation or use.
Solvonis has developed three additional chemically distinct supporting patent families through the programme, all of which have now achieved composition-of-matter grant or allowance in either the US or Europe. A corresponding US application remains pending, with examination also requested in Canada. PTSD affects an estimated 15.8 million people across the US, UK, EU4 and Japan, a market the company noted is attracting significant pharmaceutical investment despite existing approved treatments.
Chief executive Anthony Tennyson said the allowance strengthens the proprietary position roughly SVN-114, adding that its differentiated profile and broad IP estate provide a strong foundation for long-term value creation. For Solvonis, shares of which trade at 0.1175p, building a defensible composition-of-matter estate across multiple jurisdictions ahead of full US grant materially improves the asset's licensing and partnership prospects in a CNS field where intellectual property strength is often the deciding factor in pharma dealmaking.
